Redmile Group’s Unity Biotechnology UBX Stock Holding History

Redmile Group’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,040	Closed	-$3.77M	–	95
2018 Q2	$3.77M	Buy	+25,040	New	+$3.66M	0.13%	64

Other funds holding UBX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

NTC

NF Trinity Capital Central, Hong Kong $626M AUM 3.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group's UBX Position: Q3 2018 in Review

Redmile Group sold out of Unity Biotechnology (UBX) in Q3 2018, closing a stake of 25,040 shares — an estimated $3.77M sold.

Redmile Group first reported a position in UBX in Q2 2018 and held it in 1 quarter. The position peaked at $3.77M in Q2 2018. 42 funds tracked by Wall St. Rank hold UBX as of Q3 2018.

Redmile Group reported no remaining Unity Biotechnology position as of Q3 2018 after selling out during the quarter.
Redmile Group sold 25,040 Unity Biotechnology shares in Q3 2018, an estimated $3.77M.
Redmile Group first reported a position in Unity Biotechnology in Q2 2018 and held it in 1 quarter.
Redmile Group's Unity Biotechnology position peaked at $3.77M in Q2 2018.
42 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2018.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.